Define your own pathway to the paperless QC laboratory: lessons learned from an ongoing project
Presenter: Sergio Nasi, Head of IT Operations Laboratory Execution at Boehringer-Ingelheim
Going paperless is an endeavor that oftentimes is predominantly interpreted as mere selection of the vendor that provides the most appropriate product. But a correct analysis of the stakeholders that have an interest in achieving paperless capabilities, a fact driven prioritization of processes involved and a thorough evaluation of interfaces to existing systems are equally if not even more important factors to consider.
In this keynote, an overview of how such aspects have been evaluated in an ongoing implementation of a laboratory execution system at Boehringer Ingelheim’s will be discussed and what additional challenges and opportunities the global COVID-19 pandemic have meant to the project implementation.
Family-owned since it was established in 1885, its workforce of 50,000 employees creates value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals.
In 2019, Boehringer Ingelheim achieved net sales of nearly 19 billion euros. R&D expenditure, exceeding 3.4 billion euros, corresponded to more than 18.0 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research.